

respondents (“Defaulted Respondents”) did not file any response to the complaint and notice of investigation or to the order to show cause for failure to do so.

On July 21, 2025, Complainants filed a motion for summary determination of violation, and on July 22, 2025, Complainants filed a motion for leave for acceptance of a corrected motion for summary determination, which was granted pursuant to Order No. 15 (July 22, 2025). On August 4, 2025, OUII filed a response in support of Complainants’ motion.

On September 10, 2025, the ALJ issued the subject ID granting the motion for summary determination of violation and finding the remaining four respondents in default. The ID also included a recommended determination on remedy and bonding. No petitions for review of the ID were filed.

On December 15, 2025, the Commission determined to review the ID’s findings with respect to the economic prong of the domestic industry requirement. 90 FR 59203–04. The Commission determined not to review the other findings in the ID. *Id.* The Commission requested briefing from the parties regarding the allocation of certain domestic industry expenditures and the foreign respondents’ alleged domestic inventories and operations. *Id.*

On January 5, 2026, Complainants and OUII filed initial submissions in response to the Commission’s notice. On January 12, 2026, OUII filed a reply submission.

Having reviewed the record of the investigation, including the ID, the pleadings, and the parties’ submissions, the Commission has determined to affirm the ID’s finding that the economic prong of the domestic industry requirement has been satisfied with supplemental findings and modified reasoning. Accordingly, as set forth in the Commission’s opinion, the Commission finds a violation of section 337 has occurred.

The Commission has determined that the appropriate remedy is a GEO prohibiting the unlicensed entry of electrolyte containing beverages and labeling and packaging thereof that infringe one or more of the Asserted Trademarks.

Chair Karpel would issue both the GEO and CDOs directed to the Defaulted Respondents pursuant to section 337(g)(1) because all of the criteria of subsection 337(g)(1)(A)–(E) are met. The

four Defaulted Respondents were named in the Complaint and served with the Complaint and notice of investigation. *See* Order No. 9 (Apr. 18, 2025). The ALJ issued a show cause order ordering these respondents to show cause why they should not be held in default for failing to respond to the Complaint and notice of investigation. *Id.* None of those respondents filed a response to the show cause orders. *See* Order No. 18 at 4, *unreviewed in pertinent part by* Notice, 90 FR at 59203–04. These findings satisfy subsections 337(g)(1)(A)–(D). Complainants requested CDOs limited to each of these Defaulted Respondents (*Id.* at 58 (citing SD Mem. at 67), thus satisfying subsection 337(g)(1)(E). Given that subsections 337(g)(1)(A)–(E) are satisfied with respect to the Defaulted Respondents and Complainants requested CDOs directed to these Defaulted Respondents, the statute directs the Commission to issue the requested CDOs, subject to consideration of the public interest. Chair Karpel finds that the public interest factors as detailed in Part V(B) of the Opinion do not support a finding that the requested GEO and CDOs would be contrary to the public interest. Accordingly, in addition to the GEO, Chair Karpel would issue CDOs against the Defaulted Respondents under section 337(g)(1).

The Commission has determined that the public interest factors enumerated in subsections (d)(1), (f), and (g)(1) of section 337 do not preclude the issuance of the GEO. The Commission has further determined that the bond during the period of Presidential review pursuant to section 337(j) (19 U.S.C. 1337(j)) shall be set in the amount of one hundred percent (100%) of the entered value of the articles that are subject to the GEO. The Commission’s remedial orders were delivered to the President and to the United States Trade Representative on the day of their issuance. The investigation is hereby terminated.

The Commission vote for this determination took place on March 26, 2026.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: March 26, 2026.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2026–06125 Filed 3–27–26; 8:45 am]

BILLING CODE 7020–02–P

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–1691]

**Bulk Manufacturer of Controlled Substances Application: Chemtos, LLC**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Chemtos, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 29, 2026. Such persons may also file a written request for a hearing on the application on or before May 29, 2026.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on February 13, 2026, Chemtos, LLC, 16713 Picadilly Court, Round Rock, Texas 78664–8544, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
4-Chloromethcathinone .....	1239	I

Controlled substance	Drug code	Schedule
1-(4-methoxyphenyl)-N-methylpropan-2-amine .....	1245	I
4,4'-Dimethylaminorex .....	1595	I
4F-MDMB-BINACA (4F-MDMB-BUTINACA or methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate).	7043	I
MDMB-4en-PINACA (methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate) .....	7090	I
2-(Ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine) .....	7286	I
Alpha-Pyrrolidinoheptaphenone (PV8) .....	7548	I
1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one .....	7552	I
Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) .....	9751	I
Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine) .....	9756	I
Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine) .....	9757	I
N-Pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) .....	9758	I
Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine) .....	9759	I
2-(4-Methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (N-pyrrolidino metonitazene) .....	9762	I
5-Nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (N-pyrrolidino protonitazene) .....	9763	I
Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine) .....	9764	I
Etodesnitazene; etazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) .....	9765	I
2-(2-(Benzodioxol-5-ylmethyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine .....	9766	I
2-(2-(4-Ethoxybenzyl)-5-methyl-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine .....	9767	I
2-(2-(4-Ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N-ethylethan-1-amine .....	9768	I
N-Ethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine .....	9769	I
2-(2-(2,3-Dihydrobenzofuran-5-yl)methyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine .....	9770	I
2-(2-(4-Ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-dimethylethan-1-amine .....	9771	I
2-(4-Isopropoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole .....	9772	I

The company plan to bulk manufacture the listed controlled substances for distribution as reference standards to its customers. No other activities for these drug codes are authorized for this registration.

**Thomas Prevoznik,**  
Deputy Assistant Administrator.  
[FR Doc. 2026-06052 Filed 3-27-26; 8:45 am]  
**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**  
[Docket No. DEA-1690]

**Importer of Controlled Substances Application: Usona Institute**

**AGENCY:** Drug Enforcement Administration, Justice.  
**ACTION:** Notice of application.

**SUMMARY:** Usona Institute. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on, or objections to the issuance of the proposed registration on or before April 29, 2026. Such persons may also file a written request for a hearing on the application on or before April 29, 2026.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically

through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on March 2, 2026, Usona Institute, 2780 Woods Hollow Road, Room 2412-2413, Fitchburg, Wisconsin, 53711-5370, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Mescaline .....	7381	I

Controlled substance	Drug code	Schedule
5-Methoxy-N-N-dimethyltryptamine.	7431	I
Dimethyltryptamine .....	7435	I
Psilocybin .....	7437	I
Psilocyn .....	7438	I

The company plans to import the listed controlled substances for research and analytical purposes. The materials will not be used for clinical trials or human consumption. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**Thomas Prevoznik,**  
Deputy Assistant Administrator.  
[FR Doc. 2026-06051 Filed 3-27-26; 8:45 am]  
**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-1692]

**Importer of Controlled Substances Application: Pharmaron Manufacturing Services (US) LLC**

**AGENCY:** Drug Enforcement Administration, Justice.